Management of post‐transplant lymphoproliferative disorders
- 9 May 2018
- journal article
- review article
- Published by Wiley in British Journal of Haematology
- Vol. 182 (3), 330-343
- https://doi.org/10.1111/bjh.15263
Abstract
The post‐transplant lymphoproliferative disorders (PTLDs) are a heterogeneous group of neoplasms that are one of the most serious complications of bone marrow and solid organ transplants. Because these disorders are rare, there are no randomized trials from which to derive optimal treatment. Management can be challenging and must balance the goal of PTLD eradication with the risks of graft rejection, graft‐versus‐host disease, further delays in immune reconstitution and life‐threatening infections, among others. This paper will provide a comprehensive review of PTLD following solid organ transplant and haematopoietic stem cell transplant with a focus on management. Included is a discussion of novel agents that are being studied in clinical trials and, when combined or sequenced with conventional therapy, have the potential to improve outcomes.Keywords
This publication has 99 references indexed in Scilit:
- Association of HLA Polymorphisms with Post-transplant Lymphoproliferative Disorder in Solid-Organ Transplant RecipientsAmerican Journal of Transplantation, 2011
- Lymphomas differ in their dependence on Epstein-Barr virusBlood, 2011
- Reduction of Immunosuppression as Initial Therapy for Posttransplantation Lymphoproliferative Disorder★American Journal of Transplantation, 2011
- Successful treatment of EBV-associated posttransplantation lymphoma after cord blood transplantation using third-party EBV-specific cytotoxic T lymphocytesBlood, 2010
- Rituximab Administration within 6 Months of T Cell-Depleted Allogeneic SCT is Associated with Prolonged Life-Threatening CytopeniasTransplantation and Cellular Therapy, 2010
- Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lymphomaBlood, 2010
- How I treat EBV lymphoproliferationBlood, 2009
- Guidelines for Preventing Infectious Complications among Hematopoietic Cell Transplantation Recipients: A Global PerspectiveTransplantation and Cellular Therapy, 2009
- Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantationBlood, 2009
- Epstein–Barr virus, rapamycin, and host immune responsesCurrent Opinion in Organ Transplantation, 2008